Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.22B P/E - EPS this Y 1.70% Ern Qtrly Grth -
Income -220.31M Forward P/E -6.79 EPS next Y 31.90% 50D Avg Chg 8.00%
Sales 295.21M PEG -0.08 EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book 1.74 EPS next 5Y 150.00% 52W High Chg -64.00%
Recommedations 2.10 Quick Ratio 4.37 Shares Outstanding 58.59M 52W Low Chg 87.00%
Insider Own 1.72% ROA -16.39% Shares Float 57.70M Beta 1.76
Inst Own 109.18% ROE -38.36% Shares Shorted/Prior 8.94M/9.21M Price 21.39
Gross Margin 40.53% Profit Margin -74.63% Avg. Volume 1,268,609 Target Price 53.49
Oper. Margin -54.00% Earnings Date Nov 15 Volume 1,361,700 Change -6.55%
About Twist Bioscience Corporation

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Twist Bioscience Corporation News
11/20/24 Twist Bioscience Full Year 2024 Earnings: EPS Misses Expectations
11/19/24 Twist Bioscience price target lowered to $52 from $55 at Barclays
11/19/24 Twist Bioscience Corporation (TWST): Among the Best Genomics Stocks to Buy Right Now
11/19/24 Company News for Nov 19, 2024
11/19/24 Q4 2024 Twist Bioscience Corp Earnings Call
11/19/24 Twist Bioscience Corp (TWST) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...
11/18/24 Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps
11/18/24 Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
11/18/24 Twist Bioscience: Fiscal Q4 Earnings Snapshot
11/18/24 Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results
11/14/24 Twist Bioscience to Present at 7th Annual Evercore HealthCONx Conference
11/07/24 Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
11/04/24 Adma Biologics (ADMA) Soars 18.8%: Is Further Upside Left in the Stock?
10/31/24 Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
10/30/24 Twist Bioscience Launches FlexPrep™ Ultra-High Throughput Library Preparation Kit for Applications in Agrigenomics and Population Genomics
10/24/24 Twist Bioscience to Report Fiscal 2024 Fourth Quarter and Full Year Financial Results on Monday, November 18, 2024
10/22/24 Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash
10/15/24 Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer
09/13/24 Investors ignore increasing losses at Twist Bioscience (NASDAQ:TWST) as stock jumps 11% this past week
09/12/24 Twist Bioscience Achieves LEED Certification for Sustainable Operations and Maintenance
TWST Chatroom

User Image GenomicsGeek Posted - 1 day ago

@LabPsycho Take a look at Twist Bioscience ($TWST)—a biotech company I’ve recommended before. They’re up an impressive 65% over the past year and continuing to show strong performance.

User Image WantedToRetireEarly Posted - 1 day ago

$TWST $DNA Barclays lowered the firm’s price target on Twist Bioscience (TWST) to $52 from $55 and keeps an Overweight rating on the shares. The company reported a solid quarter with a fiscal 2025 guide better than expectations despite a tough budgetary macro environment, the analyst tells investors in a research note. The firm sees the business as still on track to deliver 50% gross margins in Q4.

User Image erevnon Posted - 2 days ago

Baird maintains Twist Bioscience $TWST at Outperform and raises the price target from $46 to https://marketsblock.com/stock-upgrades-and-downgrades/

User Image Thestocktraderhubzee Posted - 2 days ago

$TWST Scotiabank Maintains Sector Outperform on Twist Bioscience, Raises Price Target to $54

User Image RemitTekram Posted - 2 days ago

$TWST True then....True now.

User Image DonCorleone77 Posted - 2 days ago

$TWST Twist Bioscience price target lowered to $52 from $55 at Barclays Barclays lowered the firm's price target on Twist Bioscience to $52 from $55 and keeps an Overweight rating on the shares. The company reported a solid quarter with a fiscal 2025 guide better than expectations despite a tough budgetary macro environment, the analyst tells investors in a research note. The firm sees the business as still on track to deliver 50% gross margins in Q4.

User Image Article_AI Posted - 3 days ago

$TWST Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps On Monday, Twist Bioscience Corporation TWST reported a fourth-quarter loss per share of 59 cents, beating the consensus loss of 70 cents. https://www.stck.pro/news/TWST/93475239/

User Image Carter316 Posted - 3 days ago

$AZI nice set up here 13gs, insiders loaded Institutions including Citadel loaded High short interest $TWST good gains here too

User Image DomLuminous Posted - 3 days ago

$TWST This company needs less talk about the future and show us the future with results.

User Image Lincoln1962 Posted - 3 days ago

$TWST

User Image DonCorleone77 Posted - 3 days ago

$NVDA $TWST $MARA $BTDR $CYBN Feel free to follow me for pre-market and after hours movers every day. PRE-MARKET MOVERS: Currently Higher After Earnings: -- Twist Bioscience (TWST) up 13.7% -- Brady (BRC) up 3.8% Currently Also Higher: -- Liberty Energy (LBRT) up 5.6% after President-elect Donald Trump nominated Chris Wright, Liberty's founder, chairman of the board, director and CEO, for the position of U.S. Secretary of Energy -- Target Hospitality (TH) up 6.9% after extending its contract with Pecos Children's Center and reaffirming its FY24 outlook -- Tesla (TSLA) up 5.9% after Bloomberg reported members of President-elect Donald Trump's transition team have told advisers they plan to make a federal framework for fully self-driving vehicles one of the Transportation Department's priorities -- Newmont (NEM) up 3.0% after agreeing to sell its Musselwhite operation in Ontario, Canada, to Orla Mining (ORLA) for up to $850M in total consideration -- CVS Health (CVS) up 2.0% after appointing four new board members following discussions and an agreement with Glenview Capital Management -- Cybin (CYBN) up 12.0% after data demonstrates 'breakthrough 12-month efficacy' in MDD treatment Currently Lower After Earnings: -- Bitdeer Techs (BTDR) down 3.7% Currently Also Lower: -- MARA Holdings (MARA) down 7.2% after announcing private offering of $700M of convertible notes -- Spirit Airlines (SAVE) down 5.6% after entering into a restructuring support agreement supported by a supermajority of Spirit's loyalty and convertible bondholders on the terms of a balance sheet restructuring -- Nvidia (NVDA) down 1.9% after The Information reported Nvidia is grappling with new problems related to its Blackwell graphics processing units for artificial intelligence, namely, how to prevent them from overheating when connected together in the customized server racks it has designed

User Image RemitTekram Posted - 3 days ago

$TWST Cheers to the BULLS for >+10% today!! What a keeper. Never even think of selling this one. Been here since the teens and not worried one bit. But man look at the manipulation last week.

User Image GetVector Posted - 3 days ago

Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves. VI will select up to 4 stocks per day. Today's VI stocks: $NGNE, $RGNX, $TWST.

User Image smartstockwatch Posted - 3 days ago

$TWST Twist Bioscience 2024 Q4 & Full Year Earnings: Twist Bioscience reported record revenue growth and improved margins in Q4 2024, beating EPS expectations. • Revenue: $313.0M, up 28% FY2024 • Adj. EPS Q4: -$0.59 vs. forecast -$0.73 (3 analysts) • Gross Margin Q4: 45.1%, up 8.5 points • FY2025 Revenue Guidance: $367M-$377M "Exiting fiscal 2024, we saw another quarter of record revenue and our seventh consecutive quarter of revenue growth. We continue to leverage our proprietary platform to add to our portfolio of solutions that deliver growth and margin expansion including our Express portfolio, NGS tools and recently, Twist-developed enzymes." - Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience Check out our video for detailed analysis: https://youtu.be/LL6RetDIbh8?si=yZycYRw9JXF12izT

User Image OpenOutcrier Posted - 3 days ago

$TWST (+13.9% pre) Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results https://ooc.bz/l/48479

User Image jeremyrun Posted - 3 days ago

$ARKG Nice earnings $TWST . Now let's see how $ARKG price responds. Largest holding.

User Image briefingcom Posted - 3 days ago

Gapping up: $CYBN +22.3% $RGNX +19.3% $ADVM +14.5% $TWST +14% $TUYA +11.8%

User Image JasonCO Posted - 3 days ago

$TWST nice er

User Image DonCorleone77 Posted - 3 days ago

$TWST Twist Bioscience sees FY25 revenue $367M-$377M, consensus $373.17M Sees FY25 adjusted EBITDA loss $60M-$65M. Sees FY25 gross margin 48%. Leproust continued, "As we head into fiscal 2025, we're building on this momentum as we continue our final push toward achieving adjusted EBITDA breakeven while investing in research and development to deliver precision, efficiency and scalability in products and services that continue to generate profitable growth."

User Image DonCorleone77 Posted - 3 days ago

$TWST Twist Bioscience sees Q1 revenue $87M, consensus $84.27M Sees Q1 adjusted EBITDA loss $20M with sequential improvements throughout 2025.

User Image DonCorleone77 Posted - 3 days ago

$TWST Twist Bioscience reports Q4 EPS (59c), consensus (69c) Reports Q4 revenue $84.71M, consensus $82.66M. Total orders received grew 24% to $88.2M. "Exiting fiscal 2024, we saw another quarter of record revenue and our seventh consecutive quarter of revenue growth. We continue to leverage our proprietary platform to add to our portfolio of solutions that deliver growth and margin expansion including our Express portfolio, NGS tools and recently, Twist-developed enzymes. We ended the quarter and the year exceeding our guidance across the board, closing out the fiscal year with $313.0 million in revenue, a gross margin of 45.1% in 4QFY24 and a strong cash position," said Emily Leproust, CEO and co-founder of Twist Bioscience.

User Image Estimize Posted - 3 days ago

Wall St is expecting -0.69 EPS for $TWST Q1 [Reporting 01/31 BMO] http://www.estimize.com/intro/twst?chart=historical&metric_name=eps&utm_c

User Image Stocktwits Posted - 3 days ago

Top Pre-Market earnings for tomorrow 👇 1) $BTBT 2) $BTDR 3) $EH 4) $BRC 5) $TWST Make sure to tune in to their earnings calls right here on Stocktwits!

User Image Plan2TradeTrade2Plan Posted - 3 days ago

$TWST perhaps $twst is the nvida of bio but is just caught up in the poor U.S. election decision affecting bio.

User Image WOLFSTREET Posted - 3 days ago

$TWST 📈CC🧭Update: Anyone not on my STREET may have trouble understanding, in any case, this opportunity remains viable. I understand the recent drawdown may be difficult, but it is part of being an investor and also using the 📈CC🧭platform. For instance, $SHOP pullback after I 1st talked it up was also difficult, but I continued to but into the drawdown since my approach is always one of scaling in either when it pulls back or even when it runs since Ihave CC certainty that it will continue, now look at SHOP, another 📈CC🧭Winner, and there are so many. $PLTR was one I continued to buy after 1st buying about $15... So be patient with your trades, the market, and mostly yourself :), after all, the 📈CC🧭, while not perfect, it rarely dissappoints.

User Image madnessofcrowds Posted - 5 days ago

$TWST all these names are still rangebound. for how much longer I do not know.

User Image Plan2TradeTrade2Plan Posted - 5 days ago

$TWST too bad they report on Black Monday

User Image padd1 Posted - 6 days ago

$TWST Short Report: The emergence of fake gross margins at growth companies; Twist Biosciences $TWST as a case study in gross margin fraud, specifically. *If you are mainly interested in $TWST, scroll down to #5 and 6 below. We remain short as we think it’s a zero.

User Image padd1 Posted - 6 days ago

Scorpion capital is short TWST 1/3 THREAD: The emergence of fake gross margins at growth companies; Twist Biosciences $TWST as a case study in gross margin fraud, specifically. *If you are mainly interested in $TWST, scroll down to #5 and 6 below. We remain short as we think it’s a zero. EBITDA gained prevalence in the 1970's when John Malone at TCI needed a way to alchemically convert negative cash flows into positive ones by removing interest expense and depreciation, given massive debt and capital expenditure at cable companies. This conditioned Wall Street to look away from cash flows that were permanently negative toward a garbage non-GAAP measure instead. The practice gained further popularity with LBO firms in the 1980's as a way to strip out the cost of debt service. When EBITDA became too high a bar, companies started shifting to "Adjusted EBITDA" and other even more creative variants. Over the last 10-15 years,

User Image FlynancialAnalyst Posted - 6 days ago

@Doozio $ARKG lol 🙄🤮🤮 $TWST

Analyst Ratings
Evercore ISI Group Outperform Oct 1, 24
Barclays Overweight Aug 5, 24
JP Morgan Underweight Aug 5, 24
Baird Outperform Aug 5, 24
Goldman Sachs Buy Jul 9, 24
Barclays Overweight Jun 28, 24
TD Cowen Buy Jun 13, 24
Guggenheim Buy Jun 5, 24
Scotiabank Sector Outperform May 6, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Green Paula SVP of Human Resourc.. SVP of Human Resources Sep 16 Option 5.95 8,514 50,658 22,610 09/20/22
Green Paula SVP of Human Resourc.. SVP of Human Resources Sep 16 Sell 37.43 8,514 318,679 14,199 09/20/22
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Aug 16 Option 11.59 9,000 104,310 47,831 08/18/22
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Aug 16 Sell 50.06 13,900 695,834 38,831 08/18/22
Banyai William See Remarks See Remarks Jul 22 Sell 43.19 378 16,326 258,729 07/26/22
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Apr 14 Option 20.53 6,620 135,909 53,308 04/18/22
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Apr 14 Sell 43.12 6,620 285,454 46,688 04/18/22
Banyai William See Remarks See Remarks Apr 01 Sell 53.61 318 17,048 262,455 04/05/22
Banyai William See Remarks See Remarks Feb 18 Sell 52.66 1,280 67,405 263,073 02/23/22
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Feb 18 Option 25 3,517 87,925 51,442 02/23/22
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Feb 18 Sell 52.86 4,442 234,804 47,000 02/23/22
Banyai William See Remarks See Remarks Jan 24 Sell 54.73 348 19,046 265,174 01/26/22
Banyai William See Remarks See Remarks Oct 22 Sell 117.39 19,791 2,323,265 306,378 10/26/21
Leproust Emily M. President & CEO President & CEO Oct 21 Option 5.95 1,740 10,353 174,222 10/25/21
Leproust Emily M. President & CEO President & CEO Oct 21 Sell 120.99 1,740 210,523 172,482 10/25/21
Weiss Patrick Chief Operating Offi.. Chief Operating Officer Oct 13 Option 20.17 4,906 98,954 53,902 10/15/21
Weiss Patrick Chief Operating Offi.. Chief Operating Officer Oct 13 Sell 104 4,906 510,224 48,996 10/15/21
Banyai William See Remarks See Remarks Oct 13 Option 7.39 28,181 208,258 326,457 10/15/21
Leproust Emily M. President & CEO President & CEO Oct 13 Option 5.95 1,740 10,353 174,222 10/15/21
Leproust Emily M. President & CEO President & CEO Oct 13 Sell 110.16 1,740 191,678 172,482 10/15/21
Leproust Emily M. President & CEO President & CEO Oct 06 Option 5.95 8,700 51,765 174,222 10/08/21
Leproust Emily M. President & CEO President & CEO Oct 06 Sell 99.05 8,700 861,735 172,482 10/08/21
Leproust Emily M. President & CEO President & CEO Sep 13 Sell 118.46 29,587 3,504,876 219,143 09/13/21
Leproust Emily M. President & CEO President & CEO Sep 13 Option 7.39 29,587 218,648 233,063 09/13/21
JOHANNESSEN JAN Director Director Aug 20 Option 14 5,000 70,000 6,898 08/20/21
JOHANNESSEN JAN Director Director Aug 20 Sell 97.11 5,000 485,550 1,898 08/20/21
Weiss Patrick Chief Operating Offi.. Chief Operating Officer May 21 Option 20.17 4,905 98,934 57,109 05/21/21
JOHANNESSEN JAN Director Director May 21 Option 14 5,000 70,000 6,898 05/21/21
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Apr 26 Option 11.59 5,000 57,950 53,034 04/26/21
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Apr 26 Sell 133.47 5,000 667,350 48,034 04/26/21
Leproust Emily M. President & CEO President & CEO Apr 15 Sell 128.84 2,000 257,680 265,843 04/15/21
Finn Patrick John Chief Commercial Off.. Chief Commercial Officer Apr 07 Option 19.6 2,702 52,959 45,446 04/07/21
Finn Patrick John Chief Commercial Off.. Chief Commercial Officer Apr 07 Sell 126.72 2,702 342,397 42,744 04/07/21
Daniels Mark See Remarks See Remarks Feb 26 Option 23.33 620 14,465 67,546 02/26/21
Daniels Mark See Remarks See Remarks Feb 26 Sell 134.31 620 83,272 66,926 02/26/21
Banyai William See Remarks See Remarks Feb 24 Sell 144.18 20,275 2,923,250 440,987 02/24/21
Leproust Emily M. President & CEO President & CEO Feb 11 Sell 178.43 75,000 13,382,250 02/11/21
Finn Patrick John Chief Commercial Off.. Chief Commercial Officer Feb 04 Option 19.6 2,702 52,959 46,729 02/04/21
Finn Patrick John Chief Commercial Off.. Chief Commercial Officer Feb 04 Sell 183.59 2,702 496,060 44,027 02/04/21
Daniels Mark See Remarks See Remarks Feb 01 Option 8.82 377 3,325 68,577 02/01/21
Daniels Mark See Remarks See Remarks Feb 01 Sell 161.02 377 60,705 68,200 02/01/21
Green Paula SVP of Human Resourc.. SVP of Human Resources Jan 26 Sell 193 246 47,478 22,250 01/26/21
Daniels Mark See Remarks See Remarks Jan 26 Option 23.33 620 14,465 68,820 01/26/21
Daniels Mark See Remarks See Remarks Jan 26 Sell 193 905 174,665 68,200 01/26/21
Banyai William See Remarks See Remarks Jan 26 Sell 192.95 14,099 2,720,402 461,937 01/26/21
Leproust Emily M. President & CEO President & CEO Jan 19 Sell 182.92 10,000 1,829,200 421,196 01/19/21
Finn Patrick John Chief Commercial Off.. Chief Commercial Officer Jan 07 Option 19.6 2,702 52,959 46,930 01/07/21
Finn Patrick John Chief Commercial Off.. Chief Commercial Officer Jan 07 Sell 132.93 2,702 359,177 44,228 01/07/21
Daniels Mark See Remarks See Remarks Dec 29 Option 16.08 997 16,032 69,164 12/29/20
Daniels Mark See Remarks See Remarks Dec 29 Sell 167.45 997 166,948 68,787 12/29/20